The goal of this SME Instrument Phase 1 project was to elaborate a Business Plan for the commercialization of GazeLab, a computer vision-based system that accurately measures two known biomarkers, ocular motility (the movement of the muscles surrounding the eye) and pupillary dynamics (pupillography) for the early diagnosis of mental illnesses. In particular, we have gathered and processed the required information to plan the clinical validation of ocular motility as an indicator for schizophrenia. GazeLab, our all-in-one solution can be deployed as a point-of-care diagnostic tool, leading to quicker and more effective treatments for a variety of disorders.
The main objective was to determine if BCNINNOVA’s GazeLab precision biomechanical ocular measurement tool was a viable and sustainable business opportunity. It has been proven, thanks to an comprehensive market analysis, that there is a hopeful market waiting for biomarker as the abnormal eye movements existance is known by the mental health sector experts and there is no accurate way currently to measure it. The health sector is awaiting a biomarker that provides objective results for the diagnosis of squizofrenia, thus calming down the current need of the health market for an objective diagnostic tool that could be use as substitute of the current state of the art.
As it was proven that there is an interest in Gazelab device in the mental health scetor, the elaboration of a business plan took place as well as a clinical validation roadmap. It was also studied, that further technological refinement of the current device will be needed in order to launch it to the market, however GAZELAB for the health sector have proven to be commercially feasible as its the current GAZELAB for the ophtalmological sector.From an internal point of view, we have defined a concise, realistic, executable and clear clinical validation and technological adpatacion that will provide Gazelab for the mental health (GMH) with the sufficient push to become the gold standard for the diagnosis of squizofrenia.
BCNINNOVA has the adequate capacity to reorganize its workload and assimilate its organizational, cultural and market growth necessary to reach the objectives of GAZELAB for the health sector with great success. Thus, BCNINNOVA aspires at becoming an international leader of the objective diagnosis of squizofrenia.in order to achieve this goal, BCNINNOVA will seek further funding from the commission and will aply for further funding under the SME instrument programme (SME phase 2).
